<DOC>
	<DOCNO>NCT02104739</DOCNO>
	<brief_summary>This project address cardiovascular disease risk patient prediabetes . Levels lipids eat meal ( `` postprandial lipid '' ) strong independent predictor cardiovascular risk . Newer anti-diabetic agent - exenatide saxagliptin - impact lipid metabolism . These medication study effect reduce postprandial lipid level arterial dysfunction .</brief_summary>
	<brief_title>Effects Antidiabetic Medications Postprandial State Prediabetes</brief_title>
	<detailed_description>It paradox medical effort control blood glucose type 2 diabetes mellitus decrease risk cardiovascular disease . Postprandial lipid concentration strong predictor cardiovascular risk , independent traditional cardiovascular risk factor . The new class antidiabetic medication - GLP-1 agonist DPP-IV inhibitor - affect lipid well glucose metabolism . This study investigate efficacy medication reduce postprandial hyperlipidemia , disrupt concurrent proinflammatory free fatty acid signaling , ameliorate endothelial dysfunction individual prediabetes . This consist single center , randomize , crossover , placebo-controlled double-blinded prospective trial involve three study arm represent aforementioned medication : exenatide ( GLP-1 agonist ) , saxagliptin ( DPP-IV inhibitor ) , placebo ( control arm ) . For study arm , subject eat standardized atherogenic high-fat test lunch . Venous blood draw measurement forearm blood flow do prior meal periodically 6-hour period meal . Forearm blood flow measurement assess change endothelial function . The blood analyze multiple marker hyperlipidemia free fatty acid signal . After complete three randomize study visit , subject invite participate optional , nonrandomized extension study . For extension study , subject take exenatide ER ( extended-release exenatide ) weekly total six week . Then subject return eat standardize atherogenic high-fat test lunch . Venous blood draw measurement forearm blood flow do prior meal periodically 4-hour period meal , analyse describe . The result provide new insight anti-inflammatory effect multiple antidiabetic medication via mechanisms postprandial hyperlipidemia , free fatty acid signaling , endothelial function prediabetic individual .</detailed_description>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1 . Men woman , age 30 70 year age inclusive 2 . Diagnosis Prediabetes define either impaired fasting glucose ( fast glucose 100125 mg/dL ) , impair glucose tolerance ( 2hour postprandial blood glucose 140199 mg/dL 75 gram oral glucose challenge ) , and/or hemoglobin A1C range 5.7 % 6.4 % 3 . Subjects allow , require , statin , ACEinhibitors , betablockers , angiotensinreceptor blocker , thiazide diuretic , and/or loop diuretic dose stable least last 3 month 4 . BMI 3035 kg/m2 ( ±1 kg/m2 ) 5 . Body weight stable ( ±45 pound ) prior three month . 6 . Women childbearing age must agree use acceptable method pregnancy prevention ( barrier method , abstinence , surgical sterilization ) duration study 7 . Patients must follow laboratory value : Hematocrit ≥ 34 vol % S. creatinine &lt; 1.5 mg/dl men 1.4 mg/dl woman AST ( SGOT ) &lt; 2.5 time ULN , ALT ( SGPT ) &lt; 2.5 time ULN , alkaline phosphatase &lt; 2.5 time ULN 1 . History Type 1 Type 2 diabetes mellitus 2 . History diabetic ketoacidosis hyperosmolar nonketotic coma 3 . Pregnant breastfeed woman 4 . Patients must receive lipidlowering medication statin within last 3 month 5 . Patient must receive metformin , DPPIV inhibitor , GLP1 agonists , thiazolidinediones , insulin , sulfonylurea , acarbose , SGLT2 inhibitor , corticosteroid , immunosuppressive therapy within last 3 month take duration study . Patient must receive NSAIDS antioxidant vitamin within last 1 week , take duration study . 6 . Patients must hormone replacement therapy . 7 . Patients diabetic gastroparesis 8 . Patients current tobacco use 9 . Patients active malignancy 10 . Patients history urinary bladder cancer 11 . Patients dietary restriction preclude highfat meal 12 . Patients history clinically significant heart disease ( NYHA III IV ; non specific STT wave change EKG ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) study 13 . Subjects history serious hypersensitivity reaction study medication 14 . Prisoners subject involuntarily incarcerate 15 . Subjects compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness 16 . Subjects know allergic reaction study medication test meal 17 . Subjects unwilling unable provide inform consent 18 . Subjects determine investigator ( ) appropriate candidate study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>prediabetes</keyword>
	<keyword>diabetes mellitus type 2</keyword>
	<keyword>exenatide</keyword>
	<keyword>saxagliptin</keyword>
	<keyword>exenatide ER</keyword>
</DOC>